NEW YORK (GenomeWeb) – Leerink today initiated coverage of liquid biopsy-based diagnostics firm Trovagene with an Outperform rating. 

Analyst Dan Leonard gave the San Diego-based company's shares a $9 price target, and in a report, he noted the sizeable liquid biopsy market opportunity — which he pegged at a minimum of $10 billion long term — calling it "a market with the potential … to be the largest in molecular diagnostics." 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Sponsored by

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.